This company listing is no longer active
HSKN Stock Overview
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Heska Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$111.00 |
| 52 Week High | US$111.00 |
| 52 Week Low | US$56.00 |
| Beta | 1.58 |
| 1 Month Change | 4.72% |
| 3 Month Change | 37.89% |
| 1 Year Change | 37.04% |
| 3 Year Change | 39.62% |
| 5 Year Change | 18.60% |
| Change since IPO | 265.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| HSKN | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 1.7% | 1.7% |
| 1Y | 37.0% | -7.7% | 2.3% |
Return vs Industry: HSKN exceeded the German Medical Equipment industry which returned 3.9% over the past year.
Return vs Market: HSKN exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| HSKN volatility | |
|---|---|
| HSKN Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HSKN's share price has been volatile over the past 3 months.
Volatility Over Time: HSKN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 808 | Kevin Wilson | www.heska.com |
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops.
Heska Corporation Fundamentals Summary
| HSKN fundamental statistics | |
|---|---|
| Market cap | €1.21b |
| Earnings (TTM) | -€18.55m |
| Revenue (TTM) | €236.10m |
5.1x
P/S Ratio-65.4x
P/E RatioIs HSKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HSKN income statement (TTM) | |
|---|---|
| Revenue | US$254.89m |
| Cost of Revenue | US$145.47m |
| Gross Profit | US$109.42m |
| Other Expenses | US$129.45m |
| Earnings | -US$20.03m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 42.93% |
| Net Profit Margin | -7.86% |
| Debt/Equity Ratio | 22.9% |
How did HSKN perform over the long term?
See historical performance and comparison